Rienso (ferumoxytol) withdrawn

on the 16 March 2015

Iron deficiency is common in the later stages of CKD as a result of decreased renal synthesis of erythropoieses | SCIENCE PHOTO LIBRARY
Iron deficiency is common in the later stages of CKD as a result of decreased renal synthesis of erythropoieses | SCIENCE PHOTO LIBRARY

The intravenous iron preparation Rienso (ferumoxytol) has been withdrawn for commercial reasons. Launched in 2012, it was licensed for the treatment of iron deficiency anaemia in patients with chronic kidney disease.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

More from MIMS

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Long-term antipsychotic use linked to breast cancer

Long-term antipsychotic use linked to breast cancer

Recent research indicates a significant increase in...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...